Self-reported osteoporosis prevention in inhaled corticosteroid users in community pharmacy setting
Authors:
Open Access
- 1 January 2015
- journal article
- research article
- Published by SAGE Publications in Sage Open Medicine
- Vol. 3
Abstract
Objectives: The use of inhaled corticosteroids is the standard maintenance therapy in asthma therapy and as adjunct therapy in moderate to severe chronic obstructive pulmonary disease. A dose-related increase in fracture risk is associated with inhaled corticosteroid use; there is an inverse relationship between bone mineral density and duration and cumulative dose of inhaled corticosteroid. Adequate intake of calcium and vitamin D are cornerstones of osteoporosis prevention. The objectives are to assess whether the proportion of patients receiving inhaled corticosteroids are taking calcium and vitamin D; the association between long-term inhaled corticosteroid use and abnormal bone mineral density or fractures; and how many qualified patients received bone mineral density scans. Methods: Patients who filled a prescription for inhaled corticosteroids at selected community pharmacies across Alberta were recruited for a survey of their osteoporosis prevention activities. Results: A total of 256 patients from 12 community pharmacies were included. The average age was 60 ± 17.4 years with 65% female. There were 21%, 51%, and 28% of patients on high, medium, and low dose inhaled corticosteroids, respectively. Only 17% of patients >50 years old received recommended calcium and vitamin D supplementation and 87 (73%) of the qualified patients received bone mineral density scan. Conclusion: Osteoporosis prevention in inhaled corticosteroid users is currently poorly addressed. More promotion is needed to raise pharmacist awareness of the risks of inhaled corticosteroids.Keywords
This publication has 28 references indexed in Scilit:
- Impact of long‐term treatment with low‐dose inhaled corticosteroids on the bone mineral density of chronic obstructive pulmonary disease patients: Aggravating or beneficial?Respirology, 2012
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryCanadian Medical Association Journal, 2010
- Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysisBMJ, 2010
- Primary and Secondary Prophylaxis to the Use of Inhaled Glucocorticoid in Primary Health CareJournal of Asthma, 2008
- Effects of inhaled corticosteroids on boneAnnals of Allergy, Asthma & Immunology, 2005
- Asthma and Therapeutics: Inhaled Corticosteroids, Corticosteroid Osteoporosis, and the Risk of Fracture in Chronic AsthmaAllergy, Asthma & Clinical Immunology, 2004
- Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®British Journal of Clinical Pharmacology, 2001
- The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approachArthritis & Rheumatism, 1999
- Pharmacokinetics and pharmacodynamics of inhaled corticosteroidsJournal of Allergy and Clinical Immunology, 1998
- Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroidsJournal of Allergy and Clinical Immunology, 1995